Fertility Clinical Trial
— PATHSOfficial title:
The Find Your PATHS (Pragmatic Assessment of a Tool to Help Survivors) to Sexual Health and Parenthood Study
Verified date | January 2019 |
Source | American Cancer Society, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Concerns with sexual health and fertility are common among cancer patients, survivors and
their partners. Literature reviews suggest that over 60% of survivors have reproductive
health problems yet fewer than 20% get professional help. This study will test the uptake,
use and effectiveness of online, interactive self-help programs for men and women with
cancer. Participants in the study will receive up to 6 months of access to the self-help
programs without charge. Navigation through the programs can be personalized by setting goals
and following links to the most relevant information. The programs cover all cancer sites and
common treatments, explaining sexual and fertility side effects. Programs also include
step-by-step cognitive behavioral self-help exercises, guidance on available medical
treatment options, decision aids, and video stories with actual survivors as well as
vignettes with actors. Information for same-sex couples is included. Programs include
suggestions on how partners can work together to cope with sexual or fertility issues.
The primary hypothesis is that participants will report improvements in sexual function and
satisfaction from baseline to 3-month follow-up. Secondary hypotheses will investigate
whether more extensive use of the program is associated with better outcomes (dose-response
effect) and whether the intervention also improves secondary outcomes such as anxiety,
depression, relationship satisfaction, and seeking medical help. Analyses from the data will
investigate how many people who are informed of the study decide to participate (uptake), as
well as how often participants visit the program and which parts are used most. Both the male
and female programs have previously been shown to help cancer survivors and partners in
published clinical trials.
Participants will be encouraged to invite a sexual partner to join the study, but that will
be optional. Partners will be able to be linked for statistical analysis through their unique
study identification numbers. Participants' use of the websites will be electronically
tracked and compared with questionnaire outcome measures. Outcome measures include online,
self-report questionnaires completed at baseline and 3-month follow-up. At 6-month follow-up,
participants will complete 2 online ratings of the helpfulness of the programs. Privacy and
security are carefully protected. The entire website meets standards for HIPAA (Health
Insurance Portability and Accountability Act). Questionnaires are identified with study
numbers rather than names or email addresses. Once the study data are analyzed, the list
linking participant identifying information (names, email) and study numbers will be
destroyed. Any publications resulting from the study will discuss group data and will not
contain any information that could be used to identify an individual participant.
Status | Completed |
Enrollment | 361 |
Est. completion date | December 11, 2018 |
Est. primary completion date | September 11, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Has had a diagnosis of cancer or is the intimate partner of a cancer patient/survivor - Has a concern or wants to learn more about cancer-related issues with sexuality or fertility - Has a way to access the website and questionnaires on the internet Exclusion Criteria: - Younger than age 18 - Does not read and understand English well enough to use the website independently - Does not live in the United States - Potential participant has already subscribed to the male or female self-help program |
Country | Name | City | State |
---|---|---|---|
United States | Will2Love, LLC | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
American Cancer Society, Inc. | Will2Love, LLC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PROMIS® (Patient-Reported Outcomes Measurement Information System) Brief Sexual Profile v2 Male | Construct: Sexual function and satisfaction in men; Total Score Range: 0-33; Higher values represent a better outcome | Change from baseline to 3 months post consent | |
Primary | PROMIS® (Patient-Reported Outcomes Measurement Information System) Brief Sexual Profile v2 Female | Construct: Sexual function and satisfaction in women; Total Score Range: 0-49; Higher values represent a better outcome | Change from baseline to 3 months post consent | |
Secondary | PROMIS® (Patient-Reported Outcomes Measurement Information System) Brief Anxiety Scale | Construct: General anxiety level; Total Score Range: 0-16; Higher scores represent a worse outcome | Change from baseline to 3 months post consent | |
Secondary | PROMIS® (Patient-Reported Outcomes Measurement Information System) Brief Depression Scale | Construct: Depressed Mood; Total Score Range: 0-16; Higher scores represent a worse outcome | Change from baseline to 3 months post consent | |
Secondary | Abbreviated Dyadic Adjustment Scale-4 | Construct: Relationship happiness; Total Score Range: 0-21; Higher scores represent a better outcome | Change from baseline to 3 months post consent |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02759705 -
Bladder Exstrophy (FIVES FertIlity Vesical Exstrophy Sexuality)
|
||
Not yet recruiting |
NCT02534857 -
A Study Comparing a Shorter Exposure of Oocyte to Spermatozoa Versus a Standard Incubation on the Live Birth Rate of In-vitro Fertilization Treatment
|
N/A | |
Enrolling by invitation |
NCT01803893 -
Prognostic Value of PIF Detection in Embryo Culture Media Correlation With Pregnancy Outcome
|
N/A | |
Completed |
NCT01888744 -
Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist
|
Phase 4 | |
Terminated |
NCT01173276 -
Intrauterine Insemination In HIV-Discordant Couples
|
N/A | |
Not yet recruiting |
NCT03680937 -
Methods for Fertility Preservation: Impact of Vitrification on in Vitro Matured Oocytes
|
||
Completed |
NCT03455062 -
Fertility Study of Women Who Received Organ Transplantation
|
N/A | |
Completed |
NCT02736214 -
Reproductive Life Plan-based Counseling With Men
|
N/A | |
Terminated |
NCT01614704 -
Impact of Sequential Chemotherapy on Young Patients Breast Cancer Treated Fertility
|
||
Completed |
NCT01895192 -
Sperm Morphology by High Magnification in Fertility Men
|
N/A | |
Terminated |
NCT01268592 -
Fertility Preservation in Female Cancer Patients
|
N/A | |
Terminated |
NCT01232972 -
Oocyte Cryopreservation
|
N/A | |
Completed |
NCT01012596 -
Creighton Model Effectiveness, Intentions and Behaviors Assessment (CEIBA)
|
||
Completed |
NCT00390754 -
Usefulness of Home Pregnancy Testing
|
N/A | |
Completed |
NCT00231504 -
Study of Follicle Stimulating Hormone (FSH) Receptor in Women With Low Antral Follicle Count
|
Phase 1 | |
Recruiting |
NCT05414812 -
Intervening on Women's Health for Rural Young Breast Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT02661932 -
Fertility Preservation in Breast Cancer Patients
|
Phase 4 | |
Recruiting |
NCT06172504 -
Ejaculation Frequency and Semen Parameters
|
||
Recruiting |
NCT02878434 -
Fertility Preservation in Young Women With Cancer
|
||
Withdrawn |
NCT02431000 -
Male Fertility and Sperm Cryopreservation
|